Back to results
US 2026/0308219 A1Published application
Recombinant herpes simplex virus with il-12 expression
AssigneeTomoki TODO
InventorsTomoki TODO, Hiroshi FUKUHARA
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeTomoki TODO
InventorsTomoki TODO, Hiroshi FUKUHARA
Estimating the term…
An object of the present invention is to develop a novel armed oncolytic herpes simplex virus (HSV) using G47Δ as the backbone. There is provided a pharmaceutical composition comprising a recombinant herpes simplex virus (HSV) with interleukin 12 (IL-12) expression, the recombinant HSV having a gene encoding a fusion polypeptide in which the 35 kDa light chain (p35) and the 40 kDa heavy chain (p40) of IL-12 are linked via two or more elastin motifs, and having the following characteristics (a) to (c): (a) the ICP6 gene is deleted or inactivated; (b) the γ34.5 gene is deleted or inactivated; and (c) the α47 gene is deleted or inactivated.
A pharmaceutical composition comprising a recombinant herpes simplex virus (HSV) with interleukin 12 (IL-12) expression, the recombinant HSV comprising a gene encoding a fusion polypeptide in which the 35 kDa light chain (p35) and the 40 kDa heavy chain (p40) of IL-12 are linked via two or more elastin motifs, and having the following characteristics (a) to (c):
A pharmaceutical composition comprising a recombinant HSV with IL-12 expression, the recombinant HSV comprising a gene encoding IL-12, and having the following characteristics (a) to (c), which induces IFNγ production through IL-12 expression without decreasing the replication ability of the recombinant HSV:
A pharmaceutical composition for intravenous administration, comprising a recombinant HSV with IL-12 expression, the recombinant HSV comprising a gene encoding IL-12, and having the following characteristics (a) to (c):
A pharmaceutical composition for intratumoral administration, comprising a recombinant HSV with IL-12 expression, the recombinant HSV comprising a gene encoding IL-12, and the following characteristics (a) to (c), which elicits systemic anti-tumor immunity, and thereby attains either the suppression of metastasis or the suppression of growth of a tumor not receiving direct intratumoral administration, or both:
A pharmaceutical composition for treating a tumor requiring increased infiltration of immune cells comprising a recombinant HSV with IL-12 expression, the recombinant HSV comprising a gene encoding IL-12, and having the following characteristics (a) to (c):
Dependencies are inferred from the claim text.